The evidence geekery continues, and this week Helen Macdonald and Duncan Jarvies are joined again by Joe Ross, The BMJ's US research editor, and professor of medicine and public health at Yale.
This week we update you on treatment - the WHO's guidelines for covid and ivermectin, and why they're not ready to recommend it's use in treatment, and prophylactic anticoagulation treatment.
We hear about two papers from the UK and Switzerland which look at children and covid, and we pick up on varients of concern and long covid.
Reading list.
Association between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England
https://www.bmj.com/content/372/bmj.n628
Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools
https://www.bmj.com/content/372/bmj.n616
Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
https://www.bmj.com/content/372/bmj.n579
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study
https://www.bmj.com/content/372/bmj.n311
Editorial - Prophylactic anticoagulation for patients in hospital with covid-19
https://www.bmj.com/content/372/bmj.n487
Living with Covid19 – Second review - Informative and accessible health and care research
https://evidence.nihr.ac.uk/themedreview/living-with-covid19-second-review/
